|Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials|
M De Laurentiis, G Cancello, D D'Agostino, M Giuliano, A Giordano, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2008
|A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models|
X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ...
Cancer research 73 (15), 4885-4897, 2013
|Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment|
M Giuliano, A Giordano, S Jackson, KR Hess, U De Giorgi, M Mego, ...
Breast Cancer Research 13 (3), 1-9, 2011
|Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis|
G Di Lorenzo, R Autorino, G Bruni, G Carteni, E Ricevuto, M Tudini, ...
Annals of oncology 20 (9), 1535-1542, 2009
|Metastasis dormancy in estrogen receptor–positive breast cancer|
XHF Zhang, M Giuliano, MV Trivedi, R Schiff, CK Osborne
Clinical Cancer Research 19 (23), 6389-6397, 2013
|Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study|
G Di Lorenzo, WD Figg, SD Fossa, V Mirone, R Autorino, N Longo, ...
European urology 54 (5), 1089-1096, 2008
|Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2× 2 factorial, randomised phase 3 trial|
L Del Mastro, S De Placido, P Bruzzi, M De Laurentiis, C Boni, ...
The Lancet 385 (9980), 1863-1872, 2015
|Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination|
M Giuliano, A Giordano, S Jackson, U De Giorgi, M Mego, EN Cohen, ...
Breast cancer research 16 (5), 1-9, 2014
|Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy|
A Giordano, M Giuliano, M De Laurentiis, G Arpino, S Jackson, BC Handy, ...
Annals of oncology 23 (5), 1144-1150, 2012
|Perspective on circulating tumor cell clusters: why it takes a village to metastasize|
M Giuliano, A Shaikh, HC Lo, G Arpino, S De Placido, XH Zhang, ...
Cancer research 78 (4), 845-852, 2018
|The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper|
M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ...
Critical reviews in oncology/hematology 134, 39-45, 2019
|Mechanisms of lapatinib resistance in HER2-driven breast cancer|
V D’Amato, L Raimondo, L Formisano, M Giuliano, S De Placido, R Rosa, ...
Cancer treatment reviews 41 (10), 877-883, 2015
|Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer …|
R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ...
The lancet 393 (10179), 1440-1452, 2019
|Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype|
L Gerratana, D Basile, G Buono, S De Placido, M Giuliano, S Minichillo, ...
Cancer treatment reviews 68, 102-110, 2018
|Epigenetic control of gene expression: Potential implications for cancer treatment|
F Perri, F Longo, M Giuliano, F Sabbatino, G Favia, F Ionna, R Addeo, ...
Critical reviews in oncology/hematology 111, 166-172, 2017
|Biological mechanisms and clinical implications of endocrine resistance in breast cancer|
M Giuliano, R Schiff, CK Osborne, MV Trivedi
The Breast 20, S42-S49, 2011
|Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications|
F Perri, R Pacelli, G Della Vittoria Scarpati, L Cella, M Giuliano, ...
Head & neck 37 (5), 763-770, 2015
|Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications|
M Giuliano, MV Trivedi, R Schiff
Breast Care 8 (4), 256-262, 2013
|CDK 4/6 inhibitors as single agent in advanced solid tumors|
F Schettini, I De Santo, CG Rea, P De Placido, L Formisano, M Giuliano, ...
Frontiers in oncology 8, 608, 2018
|Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology|
M De Laurentiis, G Cancello, L Zinno, E Montagna, L Malorni, A Esposito, ...
Annals of Oncology 16, iv7-iv13, 2005